Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Halma, S&U, Mitie and more: What brokers said today

Will FTSE 100-listed safety equipment company Halma PLC (LSE:HLMA) deliver its 45th consecutive 5%-plus dividend increase in its upcoming full-year earnings print?

The 130-year-old Amersham-based group may not be among the sexiest of the blue-chip index’s constituents, but its investment thesis is airtight.

Read more

Supermarket Income REIT PLC (LSE:SUPR, OTC:SUPIF) has one of the strongest rental income profiles in the UK real estate investment trust sector, according to a report by Stifel.

Nearly 80% of its leases are index-linked, ensuring a stable and predictable income stream. Despite this robust profile, the American investment bank believes the equity market undervalues the company and reiterates a 'buy' rating with a price target of 100p (current price 75p).

Read more

S&U PLC (LSE:SUS) had its target price trimmed by Peel Hunt after the specialist lender spelled out the current impact of the FCA’s Financial Difficulty review.

S&U's motor finance arm Advantage has increased its levels of forbearance [repossessions], which has led to a reduction in the collections ratio (of amounts falling due) from 92.1% in 2023 to 87.1%, triggering impairment charges.

Read more

Mitie Group PLC (LSE:MTO)’s strong set of financial results surpassed City analysts’ expectations, leading to buy recommendations on the stock from brokers Stifel, Peel Hunt and Liberum.

The outsourcing company’s revenues hit a record £4.5 billion, driven by higher contract prices, growth in key accounts, a 37% rise in project upsell revenues and infill mergers and acquisitions.

Read more

Panmure Gordon repeated its 'buy' recommendation on BiVictrix Therapeutics PLC along with a 66p price target after the drug developer secured £370,000 worth of government grant funding.

The non-dilutive Innovate UK investment will bankroll the next 18 months of development of BVX002 targeting ovarian cancer.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK